China pharma M&A heats up with Luye deal

Luye Pharma Group has agreed to buy a subsidiary of Swiss counterpart Acino, becoming the latest Chinese healthcare company to look overseas for expansion.

Luye Pharma Group has agreed to buy a subsidiary of Swiss counterpart Acino, becoming the latest Chinese healthcare company to look overseas for expansion.

Luye Pharma, backed by Singapore’s sovereign wealth fund GIC, is buying a branch of Acino that makes transdermal drug delivery systems TDS, or patches. The 245 million $270 million acquisition means Luye is about to control one of the largest TDS manufacturers in Europe.

The deal is Luye Pharma’s first offshore acquisition since its listing in Hong Kong in 2014. But it comes at a time when China’s healthcare industry has been undergoing widespread change, from mass-producing...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222